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Abstract
Background: Parasitic worms represent a substantial disease burden in animals and humans worldwide. The
control of parasitic roundworms (nematodes) relies heavily on the use of anthelmintic drugs. However, widespread
drug resistance in nematodes seriously compromises the effectiveness of many anthelmintics around the world.
Thus, there is a need to discover new drugs, with unique modes of action, against parasites.
Methods: Here, we synthesised and tested 74 selective estrogen receptor modulators (SERMs) for in vitro-activity
on parasitic larvae of Haemonchus contortus (barber’s pole worm), one of the most important nematode pathogens
of small ruminants (including sheep and goats) and a key representative of one of the largest groups of parasitic
nematodes (the Strongylida) of animals. We also studied the morphology of treated and untreated larvae using
scanning electron microscopy (SEM), and assessed the agonistic/antagonistic activity of SERMs in a human
embryonic kidney cell line using a luciferase reporter assay system.
Results: We identified three SERMs (one selenophene and two thiophene-core compounds) with potent inhibitory
activities (at 3–25 μM) on the motility and development of parasitic stages of H. contortus. An SEM examination of
treated H. contortus revealed considerable damage to the cuticle of fourth- but not exsheathed, third-stage larvae;
this damage appeared to be consistent with that observed upon treatment with monepantel but not moxidectin
(control compounds).
Conclusion: The potency of the three SERMs compared favourably with commercially available anthelmintics, such
that they warrant further assessment as nematocides. Future studies could focus on assessing the selectivity of
these SERMs to parasites, characterising their target(s) and/or designing analogs that are parasite-specific.
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Background
Despite their major socioeconomic impact globally, para-
sitic worms (helminths) of animals and humans are ser-
iously neglected, in terms of funding for the research and
development of chemotherapeutics, vaccines and diagnos-
tics. The current economic losses caused by such worms to
agriculture worldwide have a substantial adverse impact on
farm profitability and exacerbate the global food shortage.
For example, roundworms (nematodes) of livestock cause
major losses to farmers due to disease, reduced weight gain,
weight loss, poor productivity (e.g. in terms of meat or milk
yields) and mortality in animals. Nematodes of the order
Strongylida are of paramount importance as pathogens of
livestock animals, such as sheep, goats, cattle and pigs,
causing gastrointestinal or respiratory diseases and associ-
ated complications. In particular, Haemonchus contortus
(the barber’s pole worm) is a highly significant pathogen of
livestock worldwide, affecting hundreds of millions of small
ruminants (including sheep and goats) and causing eco-
nomic losses [1, 2] estimated at tens of billions of dollars
per annum. This parasite feeds on blood in the stomach
(abomasum) and causes gastritis, anaemia and associated
complications as well as mortality. It is transmitted orally
from contaminated pasture to the host through a direct
life-cycle [3]: eggs are excreted in host faeces; the first-stage
larvae (L1s) develop inside eggs to then hatch (usually
within one day) and develop through to the second (L2)-
and third (L3)-stage larvae in about a week; infective L3s
are then ingested by the host, exsheath (xL3) and, after a
histotropic phase, develop through fourth (L4)-stage larvae
to dioecious adults (within three weeks) in the abomasum.
The control of H. contortus and related nematodes has
relied heavily on treatment with anthelmintic drugs, in-
cluding benzimidazoles, imidazothiazole, macrocyclic lac-
tones and amino-acetonitrile derivatives. However, the
excessive use of such drugs has led or is leading to wide-
spread resistance in these nematodes to many anthelmin-
tics of these classes [4–11], seriously compromising their
effectiveness in many regions around the world. Although
a vaccine (Barbervax®, Wormvax, Albany, Australia) was
released to support treatment programs against
haemonchosis, there is a continual need to work toward
identifying new drug targets, and developing new or re-
purposing existing compounds [12, 13].
In public-private and cross-disciplinary partnerships, we
have developed an efficient whole-organism drug-
screening assay for H. contortus for the discovery and sub-
sequent repurposing of compounds to parasitic nema-
todes [14–16]. Interestingly, recent reports have shown
that some selective estrogen receptor modulators
(SERMs) have considerable activity against protistan para-
sites, such as Leishmania [17–19] and cestodes, including
Echinococcus granulosus, Taenia crassiceps and T. solium
[20, 21]. In these cestodes, estrogen receptor-like proteins
have been identified, and the mammalian ligand (17-β-es-
tradiol) has been shown to enhance the (asexual) repro-
ductive rate of T. crassiceps [22, 23]. These studies suggest
that estrogen receptors (ERs) and associated pathways
exist in parasitic helminths and might represent possible
anthelmintic targets.
In studies directed at human applications, in order to
obtain structurally novel compounds that are relatively
straight forward to synthesize or produce, we have
sought to expand the chemical diversity of ligands for
ERs by replacing their internal scaffolding with various
heterocycles and other structurally related elements and,
in the process, we have produced and evaluated a series of
selenophene and thiophene-derived SERMs with selective
activities on ERs (including ERα and ERβ) (Hai-Bing Zhou
et al., unpublished). These findings indicated that changes
to the core structure, although remote from close contact
with residues in the ligand-binding pocket, can have a
major impact on activity; in addition, some structural al-
terations can lead to super-agonism, resulting in the com-
pound having a greater response than the endogenous
ligand [24]. Although our focus has been on selective li-
gands for ERs of mammalian cells [25–27], we were keen
to assess whether selenophene- or thiophene-core ligands,
particularly if they do not have an effect on mammalian
ERs, have an agonistic or super-agonistic activity on para-
sitic larval stages of H. contortus.
Methods
Chemistry
Unless otherwise stated, reagents and materials were ob-
tained from commercial suppliers and were used without
further purification. The tetrahydrofuran (THF) and di-
chloromethane (DCM) were dried over Na and CaCl2,
respectively, and distilled prior to use. Reactions were
monitored by thin layer chromatography (TLC), and col-
umn chromatography purification was performed using
silica gel (230–400 mesh). NMR spectra were measured
using Bruker DRX and DMX spectrometers at 400 MHz
for 1H spectra and 100 MHz for 13C spectra and cali-
brated from residual solvent signal. In the following, the
procedures for the de novo synthesis of selenophene-
and thiophene-core compounds are described below.
General procedure for the synthesis of 2,5-dibromoselenophene
In the absence of light, selenophene (5.09 g, 38.9 mmol)
was dissolved in dry N,N-dimethylformamide (DMF),
and the solution degassed. N-bromosuccinimide (NBS, 2
equiv) was added in four portions within 30 min, and
the orange solution then stirred at room temperature
(22–24 °C) for 18 h. The reaction mixture was poured
into ice water and extracted with DCM. The combined
organic phases were washed with water and brine, and
dried over Na2SO4. The removal of the solvent yielded
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10.1 g of orange liquid, which was purified by column
chromatography (silica; n-hexane); the pure product was
a colourless liquid.
General procedure for the synthesis
of 2,3,5-trisbromoselenophene
Bromine (3.1 equiv) in CHCl3 was added dropwise to a
stirred solution of selenophene (1 equiv) in CHCl3 and
AcOH at 0 °C over the course of 1 h. The reaction mix-
ture was warmed to room temperature and stirred for
12 h, and then heated to 70 °C for 5 h. Upon completion
of the reaction, the mixture was allowed to cool to room
temperature and transferred to a large beaker. Excess
bromine was evaporated at room temperature, and the
resultant mixture was diluted with CHCl3. The organic
phase was successively washed with water, diluted in
aqueous NaOH solution and brine, and then concen-
trated. The crude crystalline product was further puri-
fied by column chromatography using hexane as an
eluent to give an orange liquid.
General procedure for the Suzuki coupling reaction of
bromoselenophene with arylboronic acid
Under Ar atmosphere, a mixture of bromoselenophene
(1 equiv), arylboronic acid (3 equiv for dibromoseleno-
phenes, 4 equiv for tribromoselenophenes), Pd catalyst
(0.1 equiv), sodium carbonate (1 equiv per bromine) in
an oxygen-free toluene/water (1:1) solution was stirred
at 120 °C for 24 h, after which the reaction mixture was
cooled to room temperature. The aqueous layer was ex-
tracted with ethyl acetate. The combined organic layers
were washed with brine, dried over anhydrous MgSO4/
Na2SO4 and then filtered and concentrated in vacuum.
The product was purified by column chromatography.
General procedure for ether cleavage
Under Ar atmosphere, to a solution of methoxyphenyl
derivative 2 (1 equiv) in dry DCM at -20 °C, boron tri-
bromide (3 equiv per methoxy function) was added
dropwise. The reaction mixture was stirred at room
temperature. After 4 h, water was added to quench the
reaction, and ethyl acetate was used to extract the aque-
ous layer. The combined organic layers were washed
with brine, dried over anhydrous MgSO4/Na2SO4, and
then filtered and concentrated in vacuum. The product
was purified by column chromatography.
In total, we synthesized 52 thiophene-core analogues
using the method reported by Min et al. [24] and 22
selenophene-core analogues using established proce-
dures (Additional file 1).
Biological assay - H. contortus
The selenophene and thiophene-core ligands (n = 74)
(Additional file 1) were screened at a concentration of
20 μM on exsheathed third-stage larvae (xL3s) of H.
contortus in 96-well microculture plates (cat. no. 3635;
Corning 3650, Life Sciences, Corning, USA) using rele-
vant control compounds (i.e. moxidectin and monepan-
tel), as described previously [15]. In brief, compounds
were dissolved to a stock concentration of 10 mM in ei-
ther dimethyl sulfoxide (DMSO) or methanol (Sigma-
Adrich Scientific, St. Louis, USA). These ligands were
then individually diluted to the final concentration of
20 μM using Luria Bertani medium (LB) supplemented
with 100 IU/ml of penicillin, 100 μg/ml of streptomycin
and 2.5 μg/ml of amphotericin (LB*). Compounds were
dispensed (in triplicate) into the wells of a 96-well
microculture plate using a multichannel pipette. In
addition, the negative controls (LB*, LB* + 0.5 % solvent;
six wells each), and positive controls (20 μM of mone-
pantel; Zolvix, Novartis Animal Health, Basel,
Switzerland and 20 μM of moxidectin; Cydectin, Virbac,
Carros, France; triplicate wells) and xL3s (~300/well)
were dispensed into wells of the plate using an auto-
mated multichannel pipette (Viaflo Assist/II, Integra
Biosciences, Zizers, Switzerland). Following a 72 h incu-
bation at 38 °C and 10 % CO2, a video recording (5 s)
was taken of each well of the 96-well microculture plate
(containing xL3s) using a greyscale camera (Rolera Bolt
CMOS, Qimaging Scientific, Surrey, Canada) and a
motorised X-Y axis stage (BioPoint 2, Ludl Electronics
Products, Hawthorne, USA). Individual videos were
processed to calculate a motility index (MI) using an al-
gorithm described previously [14]. MIs were normalised
to the negative and positive controls (to remove plate-
to-plate variation) using the program Prism (v.6 Graph-
Pad Software, USA). Z’-scores were calculated to validate
the performance of the screening assay; reliable assays
achieve Z’-scores of between 0.5 and 1 [28]. A com-
pound was recorded as having an activity if it reduced
xL3 motility by ≥ 70 % following incubation for 72 h.
Subsequently, the anti-xL3 activity of individual com-
pounds was confirmed, and half maximum inhibitory
concentration (IC50) values estimated from dose–re-
sponse curves (24 h, 48 h and 72 h). Compounds that
reduced the motility of xL3s were also tested for their
ability to inhibit the motility of L4s (same protocol as for
xL3s) and/or to affect the development of xL3s to L4s [14].
Following the measurement of L4 motility, larvae were re-
incubated for 4 more days and fixed with 1 % iodine
(50 μl). Then, L4 development was assessed based on the
presence of a well-developed mouth/pharynx using a light
microscope [14] and expressed as a percentage of the total
number of larvae examined (n = 30).
All assays (to assess xL3 motility, L4 development and
L4 motility) were performed in triplicate, three times, on
separate days. Data (MI) from each assay were converted
to a percentage compared with the negative control
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(LB* + 0.5 % solvent), and IC50 values determined using
a variable slope four-parameter equation, constraining
the top value to 100 % and using a least squares (ordin-
ary) fit model (v.6 GraphPad Software). Significant dif-
ferences in IC50 values were established using the extra
sum-of-squares F-test, employing a P-value of 0.05 (v.6
GraphPad software).
Scanning electron microscopy (SEM)
SEM was used to assess whether compounds that re-
duced motility by ≥ 70 % caused structural damage to
the larval stages. The xL3s and L4s were cultivated as
described previously [14, 15]. Compounds were diluted
to a final concentration of 100 μM in LB*, and 50 μl
were transferred to wells of a 96-well microculture plate;
six wells were used for each treatment and for the nega-
tive control which contained LB* and 1 % methanol
(AR1115-P2.5 L, RCI; Labscan Limited). The xL3s and
L4s were resuspended in LB* at a density of ~6,000 per
ml, and 50 μl were transferred into individual wells.
Compounds were incubated with the larvae for 24 h at
38 °C and 10 % CO2. Following incubation, for each
treatment, the larvae from each of the six wells were
pooled into 1.5 ml Eppendorf tubes, washed 3 times in
0.9 % saline at 9,000 g and resuspended in 1 ml of
phosphate-buffered saline (PBS). Subsequently, the lar-
vae were fixed in 2.5 % glutaraldehyde in PBS for 2 h at
room temperature, rinsed three times in PBS for 15 min,
and then post-fixed in 1 % osmium tetroxide for 2 h at
room temperature. Fixed larvae were rinsed again 3
times in PBS for 15 min. Then, aliquots of concentrated
larvae (200 μl) were incubated on polyethyleneimine
(PEI)-coated glass coverslips (pre-prepared by smearing
22 mm square glass coverslips with a 0.1 % solution of
PEI and dried by heat under a cool flame). Following this
incubation, the excess supernatant was removed, and the
coverslips with adhered nematodes were dehydrated in
increasing concentrations of ethanol (10, 30, 50, 70, 90
and 100 %) in water for 30 min. The coverslips were
dried in a critical point dryer (EM CPD030, Leica, Wet-
zlar, Germany) and mounted on to aluminium stubs
(25 mm) with double-sided carbon tabs. The coverslips
were then coated with gold using a Xenosput sputter
coater (Dynavac, Australia). The larvae on the coverslips
were imaged using a field-emission scanning electron
microscope (XL30 Philips, Netherlands) at 2.0 kV using
a spot size of two; 12 representative images were taken
of each sample.
Estrogen receptor binding affinity
Relative binding affinities were determined by a competitive
fluorometric binding assay, as described previously [29].
Briefly, 40 nM fluorescence tracer (coumestrol, Sigma-
Aldrich) and 0.8 μM purified human ERα or ERβ ligand
binding domain were diluted in 100 mM potassium
phosphate buffer (pH 7.4), containing 100 μg/ml bovine γ-
globulin (Sigma-Aldrich), and an equal volume of test com-
pound was added. Incubation was for 2 h at 25 °C. The
fluorescence polarisation values were measured. Binding af-
finities are expressed as relative binding affinity (RBA)
values, with the RBA of 17-β estradiol set to 100 %. The
values given are the average ± range of two independent de-
terminations. IC50 values were calculated using a published
formula [29].
Gene transcriptional activity
The human embryonic kidney cell line, HEK 293 T, was
maintained in Dulbecco’s Minimum Essential Medium
(DMEM) (Gibco, Thermo Fisher Scientific, Scoresby,
Australia) with 10 % foetal bovine serum (FBS) (HyClone,
GE Healthcare Life Sciences, Pittsburgh, USA). Cells in
phenol red-free DMEM with 10 % FBS were plated. HEK
293 Tcells were transfected with 25 μl (per well) containing
300 ng of 3 × estrogen response element (ERE)-luciferase
reporter, 100 ng of either ERα or ERβ expression vector,
125 mM calcium chloride (GuoYao, China) and 12.5 μl
HEPES-buffered saline (2× HBS). The next day, the cells
were treated with increasing doses of ER ligands diluted in
phenol red-free DMEM with 10 % FBS. After 24 h, lucifer-
ase activity was measured using the dual-luciferase reporter
assay system (Promega, Fitchburg, USA) performed accord-
ing to the manufacturer’s protocol.
Results
Primary screening results, and half maximum inhibitory
concentrations (IC50) values of compounds with activity
on xL3 and L4 stages of H. contortus
In the primary screen of the 74 compounds (Fig. 1;
Additional file 1), one selenophene-core compound
(WZY-2) and two thiophene-core compounds (MJ-17 and
MJ-22) were found to inhibit xL3 motility by > 70 %.
Dose–response experiments showed that the IC50 values
of these compounds ranged from 6.6 μM to 25.7 μM, with
WZY-2 and MJ-22 being significantly more potent at inhi-
biting xL3 motility than MJ-17 at all three time points ex-
amined (24, 48 and 72 h) (Fig. 2; Table 1). Similar to
moxidectin, all three compounds did not become signifi-
cantly more potent over time, with no significant differ-
ence in the IC50 values of compounds at 24, 48 and 72 h
(Table 1); however, although the three test compounds
and moxidectin (control) had a more rapid effect on the
nematode than monepantel (control), as indicated by
lower IC50 values at the earlier time points (24 h and
48 h), monepantel was most potent at inhibiting xL3 mo-
tility at 72 h (Table 1). Subsequently, we assessed the de-
velopment of xL3 to L4 in the presence of each of the
three test compounds (WZY-2, MJ-22, MJ-17). All three
compounds as well as moxidectin and monepantel had an
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inhibitory effect on L4 development, which was similar to
that of moxidectin, with IC50 values for WZY-2, MJ-22
and MJ-17 ranging from 10.5 to 13.7 μM, and with the
monepantel control compound being the most potent at
inhibiting L4 development (Table 1). Compounds WZY-2,
MJ-22 and MJ-17 were also found to inhibit the motility
of L4s, with IC50 values ranging from 3.2 to 13.9 μM. Al-
though there was no observable difference in potency be-
tween WZY-2 and MJ-22 on xL3 and L4 motility at all
three time points examined, MJ-17 was significantly more
potent at inhibiting the motility of L4 (IC50: 6.1–6.2 μM)
than xL3 (IC50: 23.8–25.6 μM) at both 48 h and 72 h
(extra sum-of-a-squares F-test: F = 5.947, df = 108, P =
0.0164; Table 1; Fig. 2).
SEM of the xL3 and L4 stages of H. contortus
We examined by SEM the morphology of xL3 and L4
stages of H. contortus following incubation with 100 μM
of WZY-2, MJ-22 and MJ-17 for 24 h. Although no
structural damage was observed in xL3s compared with
the untreated control worms, distinct damage was evi-
dent on the surface of L4s treated with each of these
three compounds (Fig. 3). Compared with the surface of
L4s incubated for 24 h in the solvent (DMSO) control,
Fig. 1 a Inhibitory properties of the 74 compounds at 20 μM on exsheathed third-stage larvae (xL3s) are displayed as the percent of motility
compared with the positive (+) and negative (−) controls. Negative controls were xL3 treated with Luria Bertani (LB) medium supplemented with
100 IU/ml of penicillin, 100 μg/ml of streptomycin and 2.5 μg/ml of amphotericin (LB*) containing 0.5 % dimethyl sulfoxide (DMSO) or methanol
(MeOH); LB* + 0.5 % DMSO/MeOH. b The structures and motility indices of compounds that have a similar structure to the active compounds,
MJ-17, MJ-22 and WZY-2 (bold), are also shown for comparative purposes. The motility indices for individual compounds were calculated from
the mean of triplicate motility indices, with the variance represented by the standard error of the mean (± SEM)
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all three compounds disrupted the cross-sectional stria-
tions of the cuticle, induced the appearance of horizontal
ridges and indentations and, in some cases, resulted in
severe perturbation of the outer cuticle (Fig. 3). These
features were similar to the cuticle damage observed fol-
lowing the treatment with 100 μM of monepantel. Moxi-
dectin did not induce any cuticle damage in L4s at the
concentrations tested, which seems consistent with a
distinct mode of action (binding to ligand-gated chloride
channels), resulting in influx of chloride ions and flaccid
paralysis of the parasite [30].
Transcriptional activation assays/estrogen receptor (ER)
binding affinity
The binding affinities of the selenophene-core and
thiophene-core ligands for both ERα and ERβ were de-
termined by a competitive fluorometric receptor-binding
assay. These affinities are presented as relative binding
affinity (RBA) values, with estradiol having an affinity of
100 %. The thiophene-core compound, MJ-17, had the
highest affinity to both ERs, with RBA values of 13.07
and 17.5 for ERα and ERβ, respectively, and exhibited
ERβ selectivity. Compound MJ-22, which is an asymmet-
rically substituted compound, had lower binding affin-
ities to these ERs (RBA values of 0.97 and 0.91 for ERα
and ERβ, respectively) than corresponding symmetrical
compounds. Compound WZY-2, a selenophene-core
compound, had RBA values of 6.11 and 12.7 for ERα
and ERβ, respectively. In the ER-responsive luciferase re-
porter gene assay, the ligands WZY-2 MJ-22 and MJ-17
induced transcriptional activities of genes encoding ERα
and ERβ, based on comparison with 17β estradiol (E2).
The luciferase assay was conducted in HEK 293 T cells
transfected with the 3 × ERE-luciferase reporter. The re-
sult showed that compound WZY-2 was shown to act as
an antagonist on ERβ with an IC50 value of 3.02 μM and
Fig. 2 Dose–response curves for the effects of each of the selenophene-core (WZY-2) and thiophene-core (MJ-17 and MJ-22) compounds on parasitic
stages of Haemonchus contortus in vitro. Graphs showing the inhibition of motility of third-stage larvae (xL3s) at 24 h, 48 h and 72 h (a-c) for individual
compounds; inhibition of development (d-f) and motility (g-i) of fourth-stage larvae (L4s) after seven days. Each data point represents the mean of
three experiments (± standard error of the mean, SEM)
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a high efficacy (Table 2). Additionally MJ-17 displayed
a > 25-fold higher EC50 value on ERα and ERβ than the
corresponding 2,3-diaryl thiophenes in the micromolar
range, whereas MJ-22 profiled as a super-agonist on
both ERα and ERβ, being at least twice as efficacious on
ERβ than estradiol (Table 2).
Discussion
Infections and diseases caused by parasitic worms impose a
substantial economic burden to the livestock production in-
dustry worldwide, and cause a loss of > 5 million disability-
adjusted life years (DALYs) in humans [2, 31, 32]. The con-
trol of parasitic nematodes of animals relies heavily on the
use of chemical treatments [33]. Consequently, the identifi-
cation of new anthelmintics is pivotal to circumvent the
rapid spread and widespread occurrence of drug resistance
in parasitic nematodes populations, particularly of small ru-
minants [4–11]. In an effort to work toward identifying
possible new candidates, we screened, using a recently de-
veloped and validated in vitro-screening platform [14, 15], a
compound library containing 74 compounds, and identified
three hetero-cyclic core SERMs, designated WZY-2, MJ-22
and MJ-17, which have a potent inhibitory effect on both
the motility and development as well as the structural in-
tegrity of parasitic larvae of H. contortus in vitro.
SERMs are defined as molecules that act as antagonist
or agonist upon binding to ERs [34]. There are two well-
Table 1 Testing of selenophene and thiophene-core ligands
(WZY-2 and MJ-22, MJ-17) on Haemonchus contortus in the
biological assay. A comparison of the ‘half of the maximum inhibitory
concentration’ (IC50) values of individual ligands with those of the
two reference anthelmintics (monepantel and moxidectin)
Compounds
Time WZY-2 MJ-22 MJ-17 Monepantel Moxidectin
xL3 motility (IC50s in μM)
24 h 10.0a 6.6b 25.7a,b ~52.1 2.5
48 h 13.0c 7.2d 25.6c,d,g 6.0 2.5
72 h 12.1e 9.6f 23.8e,f,h 0.4 2.3
L4 motility (IC50s in μM)
24 h 9.3 6.4 13.9 4.3 2.2
48 h 6.1 3.2 6.2g 2.2 0.60
72 h 6.2 6.2 6.1h 3.0 0.0045
L4 development (IC50s in μM)
7 days 12.2 10.5 13.7 0.4 12.3
IC50 values with the same superscript letter are significantly different from
each other (P < 0.05)
Fig. 3 Representative scanning electron micrographs (magnification: 8,000×) of fourth-stage larvae (L4s) incubated for 24 h in either a solvent
(DMSO) control, or 100 μM of each WZY-2, MJ-22, MJ-17, monepantel or moxidectin. Scale-bars: 5 μm
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known ER subtypes in humans, ERα and ERβ, which are
proposed to contribute to the high selectivity and target-
site specificity of SERMs [34–37]. For instance, the
SERM tamoxifen, used to treat breast cancer, acts as an
antagonist of the ERα in breast parenchyma. However,
in the endometrial and skeletal tissues, this SERM acts
as an agonist on the ERβ, and can increase the risk of
uterine cancer [34, 38]. The three SERMs identified in
this screen are structurally quite distinct from tamoxifen.
MJ-17 and MJ-22 are thiophene-core compounds that
act as agonists on human receptors ERα and ERβ. By
contrast, WZY-2, a selenophene-core compound that
differs from MJ-17 at only one position on the pentane
ring (selenium instead of sulphur), acts as an antagonist
on the ERβ receptor (Table 1; Fig. 1).
Of the 74 compounds screened, nine SERMs had struc-
tural similarity to WZY-2, MJ-22 and MJ-17, but did not
have any effect on the motility of xL3s of H. contortus.
The structures of these SERMs and their ability to reduce
xL3 motility at 20 μM are shown in Fig. 1. Since selenium
is, in many respects, similar to sulfur in its properties,
from a medicinal chemistry perspective, two structural ac-
tivity relationship (SAR) classes can be categorized, de-
pending on the position of diphenyl substitution on the
heteroaryl ring, being either a 2,5-substitution to give
more “linear” molecules, such as WZY-2 and MJ-22, or a
3,4-substitution to provide a more “compact” system, such
as is the case for MJ-17.
Considering first the 2,5-diphenyl substituted series, as
exemplified by selenophene WZY-2 and thiophene MJ-
22, replacing the chloro substituents in WZY-2 with
fluoro substituents results in WZY-3, with a greatly in-
creased xL3 motility index of 100 %. Thus, the chloro
groups are highly favourable. Since WZY-3 is already
very hydrophobic, with a CLogP of 5.5, the improvement
in activity is unlikely to relate to the hydrophobicity-
induced improved transport to the parasite, but rather
an occupation of local hydrophobic binding pockets.
The ortho substitution will cause the biaryl system to be
non-planar, but this conformation should be readily
achievable in WZY-3, such that conformational prefer-
ences are unlikely to be the cause of the differential bio-
logical activities. When the selenium atom of WZY-2 is
replaced with a sulfur atom, to give MJ-29, there is a de-
crease in inhibitory activity, with an xL3 motility index
of 67 %. Further, the potent activity of MJ-22 (xL3 motil-
ity index: 6.7 %; Fig. 1) is quite remarkable, since it pos-
sesses phenolic substituents (methyl and fluoro) that
would be expected, on the basis of the above observa-
tions for WZY-2 and WZY-3, to be significantly less ac-
tive. These two observations are suggestive of an SAR
sub-stream for 2,5-diphenylthiophenes that is different
from 2,5-diphenylselenophenes, perhaps as a result of
the smaller bond lengths involved with sulfur compared
with selenium, causing a less linear overall topography.
Little more can be added to the discussion at this stage,
without an analysis of a more extensive set of 2,5-diphe-
nylthiophenes. That at least one of the phenolic hydroxy
groups of WZY-2 is important for activity is witnessed
by the limited reduction in motility of H. contortus
caused by WZY-1 (Fig. 1), the direct analogue of WZY-
2, for which both phenolic hydroxyl groups have been
methylated. WZY-4 and WZY-5 have both “lost” activity,
but multiple substituent changes in the phenyl and sele-
nophene rings make it challenging to explain the cause
of this loss of activity and to establish whether it is due
to the bromination of the selenophene or the altered
substitutions in the phenyl rings.
An analysis of the 3,4-diphenyl-substituted thiophene
series, as exemplified by MJ-17, immediately reveals that
the position of the sulfur atom is crucial for good activity,
since MJ-32, with the sulfur atom effectively rotated one
place anti-clockwise in this resultant 3,4-diphenylthio-
phene, has lost all activity. As one would not expect a
large conformational effect on these rigid scaffolds, this
result suggests that the sulfur atom in MJ-17 plays a key
role in the binding interaction with the host target, pos-
sibly through the ability of sulfur to polarize, to a great de-
gree, in order to “favourably adapt” to a protein’s “local
environment” [39, 40]. That the chloro groups assume an
Table 2 Effects of selenophene- and thiophene-core ligand conjugates on the transcriptional activities of estrogen receptors α and β
Agonist modea Antagonist modeb
ERα ERβ ERα ERβ
Cmpd EC50 (μM) Efficacy (%E2) EC50 (μM) Efficacy (%E2) IC50 (μM) Efficacy (%E2)
c IC50 (μM) Eff (%E2)
WZY-2 – -21 ± 13 – – – 73 ± 8 3.02 13.9 ± 5.3
MJ-22 0.47 117 ± 8 0.61 277 ± 15 – – – –
MJ-17 0.045 90 ± 7 0.203 57 ± 3 – – – –
aLuciferase activity was measured in HEK 293 T cells transfected with 3 × estrogen response element (ERE)-driven luciferase reporter and expression vectors
encoding estrogen receptor α (ERα) or ERβ and treated in triplicate with increasing doses (up to 10-5 M) of the compounds. Half maximal effective concentrations
(EC50) and standard deviation (mean ± SD), shown as a percentage of 10
-8 M 17β-estradiol (E2), were determined
bHalf maximal inhibitory concentrations (IC50) and standard deviation (mean ± SD) were determined in the percentage of 10
-8 M 17β-estradiol (E2) on ERα or ERβ
cERs have considerable basal activity in HEK 293 T cells. Omitted EC50 or IC50 values were too high to be determined accurately
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important role is illustrated by the fact that their absence
from MJ-35 results in a complete loss of activity. As the
chloro groups are in ortho positions, an obvious influence
on biological activity could be the direction of a favourable
binding conformation, but this could be combined with a
specific hydrophobic interaction with the target protein
(ER). It seems unlikely that these groups contribute to
transport to the site, as MJ-35 is already relatively hydro-
phobic, with a CLogP of 4.7. Poor activity for MJ-4 reveals
the importance of at least one hydroxyl group for better
activity, while similarly poor activity for MJ-33 would be
consistent with a suboptimal engagement of an ortho-
chloro binding pocket.
Potent activity in two topographically distinct series
can often suggest non-specific modes of action and, in-
deed, polyphenols are known to non-specifically alter
membranes at micromolar concentrations [41]. How-
ever, poor activity for analogs, such as WZY-3, MJ-29
and WZY-4 of the 2,5-substituted series, and MJ-32 and
MJ-35 of the 3,4-disubstitued series is reassuring, and
suggests that the activity of MJ-17 is specific. Further-
more, ERs in mammalian cell lines have been shown to
bind these two types of topographically distinct series,
and a similar SAR is observed (Table 2.). This informa-
tion is supportive of a specific SERM mode of action,
but also raises the challenge of obtaining divergent SAR
between host and parasite ERs.
Previously, SERMs, such as tamoxifen and raloxifene,
have been shown to reduce the burden of parasitic ces-
todes in experimental infections in hamsters or mice
[18, 20, 21, 23]. In particular, tamoxifen is believed to
interfere with the ER pathway in the parasite, as high
levels of estrogen have been shown to increase the via-
bility and reproductive rate of the asexual (cysticercus)
stage of T. crassiceps, and treatment with this drug was
shown to reduce the production of ER-like proteins
[22, 23]. It is possible that the SERMs studied here (i.e.
WZY-2, MJ-17 and MJ-22) might block a similar path-
way, leading to reduced motility/viability as well as fer-
tility in the ensuing H. contortus adults, an aspect
warranting future study.
Thiophene compounds, similar to MJ-22 and MJ-17,
but differing mainly by the loss of one of the phenyl
groups have been associated with anti-parasitic activity in
worms, such as H. contortus and the closely related spe-
cies, Trichostrongylus colubriformis [42]. Gonzalez et al.
[42] reported a series of thiophene analogues with potent
in vitro activity, inhibiting the motility of ensheathed L3s
of H. contortus and T. colubriformis. However, activity
against these two nematode species was not detected in
vivo in infected gerbils. This lack of in vivo activity of
these thiophene compounds was hypothesized to relate to
differences in how the drugs interact with free-living L3s in
vitro compared with parasitic L4s and adults in vivo [42].
An advantage of the present screening platform [14, 15] is
that compounds can be tested in vitro for activity on the
parasitic (i.e. xL3s and L4s) rather than free-living stages,
overcoming possible variation in efficacy linked to free-
living stage usually tested in vitro (i.e. L1-L3) vis-à-vis the
parasitic stages in vivo [42].
While WZY-2, MJ-17 and MJ-22 were initially identified
in a primary screen against the xL3 stage, all compounds
had inhibitory activity on L4s. WZY-2 and MJ-22 were
found to be significantly more potent than MJ-17 at im-
peding xL3 motility, suggesting a clear delineation in effi-
cacy between the “linear” SERM series and “compact”
SERM series. However, all compounds were found to have
a similar potency at inhibiting both motility and develop-
ment of the L4 stage. When comparing the activity of the
compounds on the two parasitic larval stages (xL3 and
L4), MJ-17 was found to be more potent at inhibiting the
motility of L4s than of xL3s. However, this was not the
case for WZY-2 and MJ-22, which were shown to have a
similar inhibitory activity on both of these larval stages.
This differential efficacy against these stages was reflected
in scanning electron micrographs, showing distinctiveness
in the phenotypes of the two larval stages following incu-
bation with each of the three SERMs (WZY-2, MJ-22 and
MJ-17) for 24 h. While no adverse effect of individual
compounds was observed on the morphology of xL3s,
despite an inhibition of their motility, treated L4s were se-
verely damaged, to a similar extent to that observed using
the equivalent dose of monepantel (Fig. 3). The differences
in the phenotype between xL3s and L4s, despite the same
loss in motility at the same concentration, could relate to
a number of reasons, such as a differing magnitude of
drug uptake by the parasite, binding to the target(s) and
accumulation therein. Indeed, a key morphological differ-
ence between xL3 and L4s is the presence of a prominent
mouth/pharynx in the L4s compared with xL3s [43, 44].
Therefore, drug uptake (via ingestion) might be consider-
ably higher in L4s through active feeding [44] than in
xL3s, in which absorption/diffusion could be mainly
trans-cuticular. Moreover, it is possible that the drug tar-
get(s), presently proposed to be ERs, might be expressed
at a higher level in the L4 stage, allowing greater binding
and accumulation of the compounds, thus effecting re-
duced motility and pronounced morphological alterations
in this developmental stage.
Conclusion
This study has identified three SERMs with potent anti-
nematode activity on parasitic larvae of H. contortus.
These SERMs might have potential as drugs against this
and related nematodes, provided that analogs can be de-
signed that act specifically on the nematode and not the
host animal. Further work needs to confirm that the tar-
get(s) of these SERMs in H. contortus are indeed ERs
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and explore their structures. The design of nematode-
specific SERMs, as probes, would also allow for explora-
tions of ERs and associated pathways in H. contortus and
related parasites.
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